Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > You guys all want in at 3.50

<< Previous

Bullboard Posts

Next >>

Comment by moosepennyon Jan 19, 2021 9:49pm

249 Views

Post# 32330754

RE:You guys all want in at 3.50

What gets me is people saying it's a p3 only worth 150m like it's a bad thing. Unless there's some serious tomfoolery going on, I think this stock represents an opportunity that only comes around a few times in one's life. Only thing I have to do is be patient. Day to day fluctuations are basically irrelevant at this point.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China